A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19

ClinicalTrials.gov · COMPLETED, 2021

152 participants

Abstract

The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.

Conditions: COVID-19.

Primary outcome: Percentage of subjects with COVID-19 disease progression.

Enrollment: 152 participants.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 152 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• ClinicalTrials.gov
• Publisher page

Related studies

• Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence PLoS ONE, 2015
• Phenolic-protein interactions: insight from in-silico analyses – a review Food Production Processing and Nutrition, 2023
• In Silico Discovery of Candidate Drugs against Covid-19 Viruses, 2020
• Neuropharmacological Effects of Quercetin: A Literature-Based Review Frontiers in Pharmacology, 2021
• In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting BMC Complementary and Alternative Medicine, 2019
• Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing Frontiers in Microbiology, 2019

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free